somatic mesenchymal stromal cells
Cell therapyexperimental
Clinical trial activity
2 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2020 (NCT04435249)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Stem CellSupplementation
Stem Cell supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06981741 | Phase 1/Phase 2 (Phase 2) | Nov 10, 2025 | BIONCaRT GmbH, Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien, Polski Bank Komorek Macierzystych JSC (PBKM) |
| NCT04435249 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2020 | Cell Therapy Catapult, Papworth Hospital, University of London, Videregen Therapeutics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BIONCaRT GmbH | For profit | 1 | 1 | 1 | 2025 |
| Cell Therapy Catapult | For profit | 1 | 1 | 1 | 2020 |
| Koordinierungszentren für Klinische Studien bzw. Zentren für klinische Studien | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Papworth Hospital | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Polski Bank Komorek Macierzystych JSC (PBKM) | Academic/Hospital | 1 | 0 | 1 | 2025 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Videregen Therapeutics | For profit | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1